Alpha Tau Medical (NASDAQ:DRTS - Get Free Report)'s stock had its "sell (d-)" rating reissued by Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.
Separately, HC Wainwright reaffirmed a "buy" rating and set a $9.00 price target on shares of Alpha Tau Medical in a research report on Wednesday, September 3rd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $9.00.
Get Our Latest Research Report on DRTS
Alpha Tau Medical Stock Up 1.0%
Shares of NASDAQ DRTS traded up $0.04 during midday trading on Wednesday, hitting $4.17. 31,926 shares of the company's stock were exchanged, compared to its average volume of 63,072. The company has a debt-to-equity ratio of 0.07, a current ratio of 10.52 and a quick ratio of 5.81. Alpha Tau Medical has a twelve month low of $2.11 and a twelve month high of $4.69. The company has a market cap of $353.70 million, a PE ratio of -8.69 and a beta of 1.07. The firm's fifty day simple moving average is $3.61 and its 200-day simple moving average is $3.12.
Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Research analysts predict that Alpha Tau Medical will post -0.45 EPS for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Alpha Tau Medical stock. Kovitz Investment Group Partners LLC lifted its holdings in Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) by 601.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 226,320 shares of the company's stock after buying an additional 194,055 shares during the quarter. Kovitz Investment Group Partners LLC owned 0.32% of Alpha Tau Medical worth $568,000 as of its most recent SEC filing. Institutional investors own 2.65% of the company's stock.
About Alpha Tau Medical
(
Get Free Report)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alpha Tau Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.
While Alpha Tau Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
